Spatial Genomics & Transcriptomics (2026-2036)
The global spatial genomics and transcriptomics market is projected to reach USD 6.5 billion by 2036 from an estimated USD 0.73 billion in 2026, at a CAGR of 24.4% during the forecast period from 2026 to 2036. The market was valued at USD 0.66 billion in 2025.
- Published
- Sep 2026
- Pages
- 176
- Format
- PDF + Excel
- Report ID
- MRHC - 1041080
- Base year
- 2025
- 2025 · BASELINE
- $660.0M
- 2036
- $6.50B
- CAGR 2026–2036
- 24.4%
2025 baseline · 2026–2036 forecast at 24.4% CAGR · hover a bar for the value
Key highlights
The global spatial genomics and transcriptomics market is projected to reach USD 6.5 billion by 2036, growing at a CAGR of 24.4% during 2026 to 2036, supported by rising use of spatial methods in oncology research, advances in next generation sequencing, and growing biomarker detection applications.
Instrument demand and consumable demand have moved in opposite directions. 10x Genomics recorded spatial instrument revenue declining 30% year over year in the fourth quarter of 2025 while spatial consumable revenue grew 14% in the same quarter, and the two demand routes are forecast separately throughout this study.
Two entrants addressed the capital barrier most commonly cited against adoption during 2026. Illumina launched its StrataMap Spatial Solution on 8 June 2026 on existing NovaSeq and NextSeq systems requiring no additional capital instrument, while Singular Genomics launched the G4X Spatial Sequencer on 17 February 2026, operating directly from FFPE tissue at 128 samples per run with per sample costs in the low hundreds.
Consolidation has reduced the number of independent participants in this market. NanoString Technologies entered Chapter 11 bankruptcy protection in February 2024 and its platforms passed to Bruker Corporation for approximately USD 392.6 million, Akoya Biosciences was acquired by Quanterix Corporation on 8 July 2025, and Vizgen merged with Ultivue after settling its patent litigation.
A cut of nearly 40% to the National Institutes of Health budget for fiscal 2026 bears directly on this market, disrupting at least 383 clinical trials covering more than 74,000 patients and constraining capital equipment purchasing more heavily than consumable consumption.
According to the International Agency for Research on Cancer, there were an estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with over 35 million new cases projected for 2050, an increase of 77%, underscoring the expanding tissue base available for spatial oncology research.
Global pharmaceutical research and development expenditure is estimated to reach USD 213 billion by 2026 from USD 179 billion in 2020, according to the International Federation of Pharmaceutical Manufacturers & Associations, a trend that continues to fund spatial analysis committed against drug discovery and biomarker programmes.
Thirteen companies are profiled in this study, spanning platform manufacturers supplying complete instrument and consumable ecosystems, reagent suppliers operating on customer owned sequencing instruments, and specialised suppliers addressing tissue preparation, proteomics, and genome assembly.
North America holds the largest revenue share in 2026, supported by the concentration of platform suppliers and pharmaceutical research spending, while Asia Pacific is expected to register the fastest CAGR on the back of expanding genomics investment in China, Japan, and India.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026 to 2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Historical Year | 2024 |
| CAGR (Value) | 24.4% |
| Format | PDF, Excel & Cloud Portal · 176 pages |
| Market Size (Value) in 2026 | USD 0.73 Billion |
| Market Size (Value) in 2036 | USD 6.5 Billion |
| Segments Covered | By Offering: Instruments; Consumables; Software & Services. By Type: Genomics; Transcriptomics. By Technology: Imaging Based; Sequencing Based. By Application: Oncology; Neurology; Other Applications. By End User: Pharmaceutical & Biotechnology Companies; Contract Research Organizations; Other End Users |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia Pacific (China, Japan, India, Rest of Asia Pacific), Latin America, and Middle East & Africa |
| Companies Profiled | 13 |
| Key Companies | 10x Genomics, Inc. (U.S.), Bruker Corporation (U.S.), Quanterix Corporation (U.S.), Illumina, Inc. (U.S.), Vizgen, Inc. (U.S.), Singular Genomics, Inc. (U.S.), Takara Bio Inc. (Japan), Oxford Nanopore Technologies Plc (U.K.), Revvity, Inc. (U.S.), Resolve Biosciences GmbH (Germany), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), BioSpyder Technologies, Inc. (U.S.) |
| Primary Reference Sources | Company annual reports, SEC filings, and investor presentations from 10x Genomics, Bruker Corporation, Quanterix, Illumina, Vizgen, Singular Genomics, Takara Bio, Oxford Nanopore, and Revvity; International Agency for Research on Cancer, GLOBOCAN 2022 estimates; World Health Organization; International Federation of Pharmaceutical Manufacturers & Associations; National Institutes of Health budget disclosures; Food and Drug Administration and European Commission regulatory filings; court records relating to NanoString Technologies' Chapter 11 proceedings; and company press releases and product documentation |
Report overview
Segments covered: offering, type, technology, application, end user. Regions: North America, Europe, Asia-Pacific.
Consumables continue to command the largest revenue share through the forecast period, a reflection of the recurring reagent and panel demand attached to an expanding installed base, while software and services register the fastest segment growth as institutions increasingly rely on outside analytical capability to convert spatial output into interpretable results.
Spatial genomics includes genomics, transcriptomic, and epigenomic profiling methods carried out in intact tissue with positional context, establishing a molecular connection between genotypes and their phenotype. Because the human body is a complex three dimensional structure, studying genomics in a spatial manner has become important for understanding disease at the tissue level. The market covers the instruments on which spatial analysis is performed, the consumables consumed with each sample, and the software and services required to convert spatial data into interpretable results.
The commercial platforms in current use divide into two technical families. Imaging based platforms, comprising 10x Genomics' Xenium, Bruker Spatial Biology's CosMx Spatial Molecular Imager, and Vizgen's MERSCOPE, use rounds of fluorescent probe hybridization and optical decoding to localize individual transcripts at or near single molecule resolution. Sequencing based platforms, comprising 10x Genomics' Visium HD and related approaches, capture transcripts on a spatially barcoded surface and sequence them. Instrument demand and consumable demand follow different determinants, since an instrument purchase is a capital decision exposed to institutional funding while consumable purchases follow the utilization of instruments already installed, and these two routes have moved in opposite directions through 2025 and 2026.
Participants in this market divide into distinct groups. Platform suppliers manufacture spatial instruments together with the proprietary consumables required to operate them. Reagent and content suppliers provide probes, panels, and library preparation chemistry consumed with each sample. Software and analysis providers supply the tools that convert spatial output into cell type maps and quantified expression. Service providers perform spatial analysis on a contract basis for institutions without their own instruments. This structure has supported strong recurring revenue for suppliers even as capital equipment purchasing has come under pressure from constrained research funding.
Market dynamics
10 factors across 5 forcesRising Applications in Drug Discovery and Cancer Research
Pharmaceutical and biotechnology companies apply spatial analysis to understand how a therapeutic candidate acts within tissue rather than in dissociated cells, since bulk expression profiling and single cell sequencing both discard the positional relationships between cell types that spatial methods retain. Oncology is the largest application in this market, supported by the International Agency for Research on Cancer's estimate of 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with over 35 million new cases projected for 2050. The most common cancers in 2022 were lung cancer at 12.4% of all cancers, female breast cancer at 11.6%, colorectal cancer at 9.6%, prostate cancer at 7.3%, and stomach cancer at 4.9%, a clinical base that continues to expand the volume of tissue available for spatial research.
Advancements in Next Generation Sequencing and Biomarker Detection
Sequencing based spatial methods capture transcripts on a spatially barcoded surface and sequence them, so the cost and throughput of the sequencing step bears directly on the cost of a spatial experiment. High throughput short read platforms now deliver a genome at approximately USD 200, and Takara Bio has stated that next generation sequencing market growth is expected to shift from simple NGS analysis to single cell analysis and then to spatial transcriptome analysis. Quanterix stated on completing its acquisition of Akoya Biosciences that the combination creates an integrated platform measuring biomarkers across the blood and tissue continuum, expanding its served addressable market from USD 1 billion to USD 5 billion.
Increasing Investment and Consolidation Activity
Capital has continued entering this market despite the constrained funding environment. Vizgen closed a USD 48 million financing on 8 January 2026, led by ARCH Venture Partners and codelivered with M Ventures and Northpond Ventures. Corporate capital has moved alongside venture capital, with Bruker Corporation acquiring the NanoString business for approximately USD 392.6 million, Quanterix Corporation completing its acquisition of Akoya Biosciences, Takara Bio USA Holdings acquiring Curio Bioscience, and MGI Tech announcing the acquisition of STOmics in March 2026. This sustained pace of investment and consolidation is expected to generate growth opportunities for participants operating in this market through the forecast period.
Table of contents
13 chapters · 106 sections · 176 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Offering | Consumables | While Software & Services |
| By Type | Transcriptomics | — |
| By Technology | — | Sequencing Based Platforms |
| By Application | Oncology | Other |
| By End User | Pharmaceutical and biotechnology companies | CROs |
By Offering
- Consumables Dominate the Market in 2026, While Software & Services Grow Fastest
- The consumables segment is expected to account for the largest share of this market, since consumables are proprietary to each platform and consumption follows the utilization of instruments already installed.
- The software and services segment is slated to register the highest growth, reflecting the analytical capability required to convert spatial output into interpretable results, while the instruments segment grows at 22.4%, the slowest of the three, reflecting the capital constraint bearing on instrument purchasing.
By Type
- Transcriptomics Holds the Larger Share in 2026, Genomics Grows Faster
- Transcriptomics is expected to account for the larger share of the market, since every commercial platform in current use measures transcripts.
- Genomics is projected to register the faster CAGR of the two segments, growing on demand from cancer research groups investigating genome organization rather than from the broader base of institutions performing expression profiling.
- Bruker's platform derived from its Acuity Spatial Genomics acquisition provides direct visualisation of the three dimensional genome in the nucleus, and suppliers have generally reached this segment through acquisition rather than internal development, since the measurement requires different chemistry from transcript detection.
- Institutions in this segment are typically already operating a transcript platform, so the purchase is incremental rather than a first entry into spatial analysis, though the narrower commercial platform set addressing genome organization limits the rate at which this segment can expand.
By Technology
- Imaging Based Platforms Lead in 2026, Sequencing Based Platforms Grow Fastest
- Imaging based is expected to account for the larger share of the market, while sequencing based is slated to register the highest growth, supported by platforms such as Illumina's StrataMap that reach customers without a capital instrument purchase.
By Application
- Oncology Dominates the Market in 2026, Other Applications Grow Fastest
- Oncology is expected to account for the largest share of the market.
- Other applications, comprising immunology and infectious disease research, are projected to register a fastest growth, while neurology remains weighted toward publicly funded academic research and is therefore more exposed to constrained research appropriation.
By End User
- Pharmaceutical & Biotechnology Companies Lead in 2026, CROs Grow Fastest
- Pharmaceutical and biotechnology companies are expected to account for the largest share of the market, since spend in this segment is committed against programme requirements rather than released annually.
- Contract research organizations are slated to register the highest growth, since outsourcing removes the capital commitment from the institution commissioning the work, while other end users, comprising academic institutes, register the lowest growth, reflecting constrained public research funding.
Geographic analysis
North America
Largest shareNorth America is expected to account for a share of the global market in 2026, supported by the concentration of leading suppliers headquartered in the region, the scale of pharmaceutical research and development activity, and an established academic research base. Within North America, the United States accounts for the largest share of the market, while a cut of nearly 40% to the National Institutes of Health budget for fiscal 2026 is expected to constrain capital equipment purchasing in the region more than consumable consumption. North America Commands the Largest Share of the Global Spatial Genomics & Transcriptomics Market in 2026
Europe
Europe with Germany accounting for the largest national share and the highest national growth, supported by its National Strategy for Genomic Medicine and an established research infrastructure built around the Max Planck Society, the Helmholtz Association, and the Leibniz Association.
Asia-Pacific
Fastest growthAsia Pacific is expected to register the fastest growth during the forecast period. China accounts for the largest share within the region, supported by domestic platform manufacture following MGI Tech's acquisition of STOmics, while India is slated to register the highest national growth. Agilent Technologies recorded Asia Pacific revenue up 14% in the quarter ended 31 July 2026 with strong growth in its genomics business, against declining academic demand globally, indicating regional demand growing while Western research markets contract.
Latin America
Latin America and the Middle East & Africa remain smaller markets, together accounting for approximately 5.0% of global revenue in 2026, with adoption concentrated within a limited number of national research institutes.
Competitive landscape
Major companies in the global spatial genomics and transcriptomics market have pursued platform launches, acquisitions, litigation settlements, and manufacturing expansion to strengthen their market positions. Established platform manufacturers supplying complete instrument and consumable ecosystems compete alongside reagent suppliers operating on customer owned sequencing instruments and specialised suppliers addressing tissue preparation, proteomics, and genome assembly.
- —
10x Genomics launched Atera during the first quarter of 2026, engineered to deliver spatial whole transcriptome analysis with single cell sensitivity at scale, with shipping expected in the second half of 2026, and raised its full year 2026 revenue guidance to USD 610 million to USD 630 million.
- —
Bruker Corporation launched the CellScape XR spatial proteomics platform and the PaintScape platform for three dimensional genome visualization at AGBT 2026, and expanded its collaboration with Noetik Inc. following a prior study of more than 3,500 patient samples using CosMx SMI.
- —
Quanterix Corporation completed its acquisition of Akoya Biosciences on 8 July 2025, issuing approximately 7.8 million shares and paying approximately USD 20 million in cash, and reported second quarter 2026 revenue of USD 32.9 million.
- —
Illumina launched the StrataMap Spatial Solution on 8 June 2026, delivering whole transcriptome profiling at single cell resolution across a 7.5 cm² capture area on existing NovaSeq and NextSeq systems, with an FFPE specific version targeted for 2027.
- —
Vizgen debuted a three dimensional Volumetric Tissue Mapping dataset in neurodegenerative brain tissue using MERFISH 2.0 chemistry at the Human Cell Atlas General Meeting in June 2026, and closed a USD 48 million financing led by ARCH Venture Partners in January 2026.
- —
Singular Genomics announced the commercial launch and United States availability of the G4X Spatial Sequencer on 17 February 2026, and opened its G4X Spatial Research Challenge offering sample based and three dimensional spatial study awards.
- —
Takara Bio USA integrated its Trekker reagent kit with Illumina's Single Cell 3' RNA Prep assay, delivering high density spatial data at single cell resolution, following its acquisition of Curio Bioscience on 15 January 2025.
- 10x Genomics, Inc. (U.S.)
- Bruker Corporation (U.S.)
- Quanterix Corporation (U.S.)
- Illumina, Inc. (U.S.)
- Vizgen, Inc. (U.S.)
- Singular Genomics, Inc. (U.S.)
- Takara Bio Inc. · Japan
- Oxford Nanopore Technologies Plc (U.K.)
- Revvity, Inc. (U.S.)
- Resolve Biosciences GmbH · Germany
- S2 Genomics, Inc. (U.S.)
- Cantata Bio (U.S.)
- BioSpyder Technologies, Inc. (U.S.)
Frequently asked questions
The global spatial genomics market covers the study of various spatial genomics & transcriptomics instruments, consumables, software, and services based on technologies like imaging and sequencing to be used in various application areas at the regional and country levels.
Cite this report
Meticulous Research. (2026). Spatial Genomics & Transcriptomics - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MRHC - 1041080). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/spatial-genomics-and-transcriptomics-market-5763